According to this, the inhibition of CXCL10 is considered beneficial in treating T-cell-mediated autoimmune diseases (Karin, 2020) such as rheumatoid arthritis (Kim et al., 2014; Yellin et al., 2012) and type I diabetes (Frigerio et al., 2002). Here, CXCL10 is linked to rheumatoid arthritis.